Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Halozyme Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
14.85B
Market cap14.85B
Price-Earnings ratio
39.11
Price-Earnings ratio39.11
Dividend yield
—
Dividend yield—
Average volume
2.03M
Average volume2.03M
High today
$133.96
High today$133.96
Low today
$129.48
Low today$129.48
Open price
$132.09
Open price$132.09
Volume
1.40M
Volume1.40M
52 Week high
$134.00
52 Week high$134.00
52 Week low
$61.23
52 Week low$61.23

Stock Snapshot

As of today, Halozyme Therapeutics(HALO) shares are valued at $129.48. The company's market cap stands at 14.85B, with a P/E ratio of 39.11.

On 2026-11-01, Halozyme Therapeutics(HALO) stock traded between a low of $129.48 and a high of $133.96. Shares are currently priced at $129.48, which is 0.0% above the low and -3.3% below the high.

Halozyme Therapeutics(HALO) shares are trading with a volume of 1.4M, against a daily average of 2.03M.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $134.00 and a 52-week low of $61.23.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $134.00 and a 52-week low of $61.23.

HALO News

Zacks 2d
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

We expect Halozyme Therapeutics (HALO Quick QuoteHALO - Free Report) to beat expectations when it reports third-quarter 2026 results on Nov. 5, after mark...

HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Simply Wall St 3d
How Royalty Revenue Growth At Halozyme Therapeutics Has Changed Its Investment Story

Halozyme Therapeutics recently featured as a top contributor in Renaissance Investment Management's Q3 2026 Large Cap Growth Strategy, supported by strong royal...

Simply Wall St 4d
Halozyme Therapeutics Could Be 16% Below Fair Value After Royalty Fueled Growth

Halozyme Therapeutics (HALO) moved into focus after strong royalty streams and the scaling of new subcutaneous therapies helped drive what investors viewed as r...

Analyst ratings

73%

of 11 ratings
Buy
72.7%
Hold
18.2%
Sell
9.1%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.